Combine searches by placing the search numbers in the top search box and pressing the search button. An example search might look like (#1 or #2) and (#3 or #4)
Latest & greatest articles for gabapentin
The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on gabapentin or other clinical topics then use Trip today.
This page lists the very latest high quality evidence on gabapentin and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.
What is Trip?
Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.
Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.
As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.
For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via firstname.lastname@example.org
Gabapentin and postoperative pain: a systematic review of randomized controlled trials Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.
The analgesic effects of perioperative gabapentin on postoperative pain: a meta-analysis Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.
The Use of Gabapentin and Tricyclic Antidepressants in the Treatment of Neuropathic Pain in Cancer Patients Evidence-Based Series 13-8 EDUCATION AND INFORMATION 2013 A Quality Initiative of the Program in Evidence-based Care (PEBC), Cancer Care Ontario (CCO) The Use of Gabapentin and Tricyclic Antidepressants in the Treatment of Neuropathic Pain in Cancer Patients L. Librach, N. Lloyd, V. Jarvis, D. Warr, A. R. Jadad, J. Wilson, M. Brouwers, R. Wong, and members of the Supportive Care (...) @mcmaster.ca EBS Citation (Vancouver Style): Librach L, Lloyd N, Jarvis V, Warr D, Jadad AR, Wilson J, et al. The use of gabapentin and tricyclic antidepressants in the treatment of neuropathic pain in cancer patients. Toronto (ON): Cancer Care Ontario; 2006 Oct 11 [Education and Information 2011 Sep]. Program in Evidence-based Care Evidence-based Series: 13-8 Education and Information 2013 EBS 13-8 EDUCATION AND INFORMATION 2013 PRACTICE GUIDELINE – page 1 Evidence-based Series #13-8: Section 1 The Use
Gabapentin for hot flashes in 420 women with breast cancer: a randomised double-blind placebo-controlled trial. Most women receiving systemic therapy for breast cancer experience hot flashes. We undertook a randomised, double-blind, placebo-controlled, multi-institutional trial to assess the efficacy of gabapentin in controlling hot flashes in women with breast cancer.420 women with breast cancer who were having two or more hot flashes per day were randomly assigned placebo, gabapentin 300 mg (...) /day, or gabapentin 900 mg/day by mouth in three divided doses for 8 weeks. Each patient kept a 1-week, self-report diary on the frequency, severity, and duration of hot flashes before the start of the study and during weeks 4 and 8 of treatment. Analyses were by intention to treat.Evaluable data were available on 371 participants at 4 weeks (119 placebo, 123 gabapentin 300 mg, and 129 gabapentin 900 mg) and 347 at 8 weeks (113 placebo, 114 gabapentin 300 mg, and 120 gabapentin 900 mg
2005LancetControlled trial quality: predicted high
Morphine, gabapentin, or their combination for neuropathic pain. The available drugs to treat neuropathic pain have incomplete efficacy and dose-limiting adverse effects. We compared the efficacy of a combination of gabapentin and morphine with that of each as a single agent in patients with painful diabetic neuropathy or postherpetic neuralgia.In this randomized, double-blind, active placebo-controlled, four-period crossover trial, patients received daily active placebo (lorazepam), sustained (...) -release morphine, gabapentin, and a combination of gabapentin and morphine--each given orally for five weeks. The primary outcome measure was mean daily pain intensity in patients receiving a maximal tolerated dose; secondary outcomes included pain (rated according to the Short-Form McGill Pain Questionnaire), adverse effects, maximal tolerated doses, mood, and quality of life.Of 57 patients who underwent randomization (35 with diabetic neuropathy and 22 with postherpetic neuralgia), 41 completed
Gabapentin for non-malignant chronic pain Gabapentin for non-malignant chronic pain Gabapentin for non-malignant chronic pain Alberta Heritage Foundation for Medical Research Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Alberta Heritage Foundation for Medical Research. Gabapentin for non-malignant chronic pain. Edmonton: Alberta (...) Heritage Foundation for Medical Research (AHFMR). Technote TN 47. 2004 Authors' objectives
The aim of this report is to describe the background and the current evidence on the safety and efficacy/effectiveness of gabapentin when used in the management of non-malignant chronic pain.
Final publication URL Indexing Status Subject indexing assigned by CRD MeSH Acetic Acids /therapeutic use; Analgesics /therapeutic use; Chronic Disease; Pain Language Published English Country of organisation Canada
Effect of gabapentin on nausea induced by chemotherapy in patients with breast cancer. In an anecdotal report, complete resolution of chemotherapy-induced nausea was seen in a patient with breast cancer, after she was placed on the anticonvulsant gabapentin. On this basis, we did an open-label study in which oral gabapentin 300 mg thrice daily was given for every other chemotherapy treatment in nine patients with breast cancer. Six of the nine reported at least a three-point improvement in peak (...) delayed nausea (on an eight-point nausea scale), and three patients had complete resolution of nausea when taking gabapentin. This preliminary evidence shows that gabapentin might have a role in treatment of chemotherapy-induced nausea.
Gabapentin for neuropathic pain: systematic review of controlled and uncontrolled literature Gabapentin for neuropathic pain: systematic review of controlled and uncontrolled literature Gabapentin for neuropathic pain: systematic review of controlled and uncontrolled literature Mellegers M A, Furlan A D, Mailis A Authors' objectives To assess the efficacy, effectiveness and side-effects of gabapentin for the treatment of neuropathic pain. Searching MEDLINE (from 1966 to March 2001), EMBASE (...) (from 1980 to March 2001), the Science Citation Index (from 1993 to September 1999), and the Cochrane Controlled Trials Register (Issue 1, 2001) were searched. The authors also searched the reference lists in retrieved articles, reviews and book chapters, and contacted content experts for other relevant studies. The terms used in the search were 'pain', 'nociceptors', 'analgesia', 'neuropathy', 'neuropathic', 'allodynia', 'hyperalgesia', 'gabapentin', 'Neurontin' and registry number '60142-96-3
Gabapentin for drug-resistant partial epilepsy. The majority of epileptic patients have a good prognosis and their seizures can be well controlled with the use of a single antiepileptic agent, but up to 30% develop refractory epilepsy, especially those with partial seizures. In this review we summarise the current evidence regarding a new antiepileptic drug, gabapentin, when used as an add-on treatment for drug-resistant partial epilepsyTo evaluate the efficacy and tolerability of gabapentin (...) when used as an add-on treatment for patients with drug-resistant partial epilepsy.We searched the Cochrane Epilepsy Group trial register, the Cochrane Controlled Trials Register of The Cochrane Library Issue 4, 1998. In addition, we contacted Parke Davis (manufacturers of gabapentin) and experts in the field to seek any ongoing studies or unpublished studies.Randomized placebo controlled double blind add-on trials of gabapentin in patients with drug-resistant partial epilepsy.Two reviewers
Gabapentin for the symptomatic treatment of painful neuropathy in patients with diabetes mellitus: a randomized controlled trial. Pain is the most disturbing symptom of diabetic peripheral neuropathy. As many as 45% of patients with diabetes mellitus develop peripheral neuropathies.To evaluate the effect of gabapentin monotherapy on pain associated with diabetic peripheral neuropathy.Randomized, double-blind, placebo-controlled, 8-week trial conducted between July 1996 and March 1997.Outpatient (...) Pain Questionnaire scores, Patient Global Impression of Change and Clinical Global Impression of Change, the Short Form-36 Quality of Life Questionnaire scores, and the Profile of Mood States results.Eighty-four patients received gabapentin and 70 (83%) completed the study; 81 received placebo and 65 (80%) completed the study. By intent-to-treat analysis, gabapentin-treated patients' mean daily pain score at the study end point (baseline, 6.4; end point, 3.9; n = 82) was significantly lower (P<.001
Gabapentin for the treatment of postherpetic neuralgia: a randomized controlled trial. Postherpetic neuralgia (PHN) is a syndrome of often intractable neuropathic pain following herpes zoster (shingles) that eludes effective treatment in many patients.To determine the efficacy and safety of the anticonvulsant drug gabapentin in reducing PHN pain.Multicenter, randomized, double-blind, placebo-controlled, parallel design, 8-week trial conducted from August 1996 through July 1997.Sixteen US (...) outpatient clinical centers.A total of 229 subjects were randomized.A 4-week titration period to a maximum dosage of 3600 mg/d of gabapentin or matching placebo. Treatment was maintained for another 4 weeks at the maximum tolerated dose. Concomitant tricyclic antidepressants and/or narcotics were continued if therapy was stabilized prior to study entry and remained constant throughout the study.The primary efficacy measure was change in the average daily pain score based on an 11-point Likert scale (0
A cost minimization study comparing vigabatrin, lamotrigine and gabapentin for the treatment of intractable partial epilepsy A cost minimization study comparing vigabatrin, lamotrigine and gabapentin for the treatment of intractable partial epilepsy A cost minimization study comparing vigabatrin, lamotrigine and gabapentin for the treatment of intractable partial epilepsy Hughes D, Cockerell O C Record Status This is a critical abstract of an economic evaluation that meets the criteria (...) . Results of the review In the absence of head to head trials, there was no evidence that the efficacy of the three drugs differed significantly. On this basis, the authors decided to conduct a cost minimization study. The side effects of the three drugs are reported in terms of incidence, the aim being to estimate the resulting level of health service utilisation. For example, 9-15% of patients on lamotrigine, 6-15% of patients on vigabatrin and 3-7% of patients on gabapentin suffer from major side
Gabapentin in partial epilepsy. UK Gabapentin Study Group. Gabapentin is an analogue of gamma aminobutyric acid (GABA) which has anticonvulsant properties in animals. In a multicentre, double-blind, placebo-controlled, parallel-group study of 1200 mg/day gabapentin as additional therapy in 127 patients with drug-resistant partial epilepsy, 25% of patients who received gabapentin had the number of partial seizures at least halved, compared with 9.8% of patients given placebo. The median (...) reduction in partial seizure frequency during 12 weeks' treatment was 29.2% with gabapentin compared with 12.5% with placebo. The mean adjusted response ratio for gabapentin (-0.192) was significantly better than the ratio of -0.060 for placebo by analysis of variance. 62% of patients who received gabapentin reported mostly mild or moderate adverse effects compared with 41% on placebo; no interactions were observed between gabapentin and other standard anticonvulsants. Gabapentin is an effective